Nanobiotix (NASDAQ:NBTX) Shares Down 4.7% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares were down 4.7% during trading on Thursday . The stock traded as low as $39.65 and last traded at $39.7250. Approximately 50,929 shares were traded during trading, a decline of 40% from the average session volume of 85,269 shares. The stock had previously closed at $41.67.

Analyst Ratings Changes

NBTX has been the topic of several research analyst reports. Leerink Partners boosted their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nanobiotix presently has an average rating of “Moderate Buy” and an average target price of $37.33.

Nanobiotix Stock Performance

The business has a 50-day moving average price of $39.55 and a two-hundred day moving average price of $36.52.

Institutional Investors Weigh In On Nanobiotix

Large investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in shares of Nanobiotix in the 4th quarter valued at about $390,000. Marshall Wace LLP purchased a new stake in shares of Nanobiotix during the fourth quarter worth approximately $220,000. Finally, Royal Bank of Canada raised its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.